24/7 Market News Snapshot 06 August, 2025 – Geron Corp (NASDAQ:GERN)

August 6, 2025

DENVER, Colo., 06 August, 2025 (www.247marketnews.com) – (NASDAQ:GERN) are discussed in this article.
Geron Corporation is experiencing a robust surge in its stock value, with shares opening at $1.30 and rallying to approximately $1.345, marking a notable increase of about 12.08% from the previous session’s close of $1.20. The trading volume has reached 22.06 million shares, indicating heightened investor interest. This positive momentum may reflect investor optimism possibly linked to the company’s recent strategic developments. Analysts suggest that sustaining trading above key support levels near $1.30 could signal continued upward momentum, while resistance levels will be critical to watch for potential profit-taking.

In a pivotal strategic move, Geron has announced the appointment of Harout Semerjian as the new President and Chief Executive Officer, effective immediately. He succeeds Dawn Carter Bir, who will remain on the Board of Directors and continue to provide her valuable insights. Semerjian brings over 30 years of extensive experience in the biopharmaceutical sector, particularly in the areas of hematology and oncology, which positions him advantageously to lead Geron into its next phase of growth.

His previous roles at prestigious organizations, including Novartis and GlycoMimetics, speak to a strong track record of successfully launching and scaling innovative therapies. Notably, Semerjian played a significant role in expanding market access for key products like Gleevec® and KISQALI® during his tenure at Novartis, underscoring his capability to propel breakthrough treatments into the market.

Researchers and analysts are optimistic that Semerjian’s leadership will enhance awareness and access to RYTELO® (imetelstat), an innovative telomerase inhibitor recently approved for specific adult patients. With the upcoming Phase 3 IMpactMF trial for relapsed/refractory myelofibrosis on the horizon, Semerjian’s vision is geared towards transformative advancements in the landscape of blood cancer treatment, aligning with Geron’s mission to improve patient outcomes.

Related news for (GERN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.